Platelet activation in patients with chronic pulmonary heart disease. Effect of dipyridamole treatment.
Plasma levels of beta-thromboglobulin (beta-TG), platelet factor 4(PF4) and platelet aggregation rate (PAR) were measured in remission phase of 15 patients affected with chronic pulmonary heart disease (CPHD). beta-TG, beta-TG/PF4, PF4 and PAR were significantly higher in the patients than in controls (P < 0.01 and 0.05, respectively). After 10 days of treatment with Dipyridamole 100mg tid, beta-TG, beta-TG/PF4 and PF4 decreased significantly compared with pretreatment values (P < 0.01 and 0.05, respectively). The results suggest that in vivo platelet activation is indeed present in patients with CPHD and that dipyridamole can antagonize platelet activation in vivo.
Zhang
X
X
Department of Geriatrics, Southwest Hospital, Chongqing.
Ling
P
P
D000368:Aged; D004176:Dipyridamole / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010978:Platelet Factor 4 / Q000378:metabolism; D011660:Pulmonary Heart Disease / Q000097:blood* / Q000188:drug therapy; D001620:beta-Thromboglobulin / Q000378:metabolism
D010975:Platelet Aggregation Inhibitors; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D004176:Dipyridamole